♣ GW Pharma launches world’s first prescription cannabis medicine Sativex in UK

GW Pharmaceuticals plc announces the UK launch of Sativex, its Oromucosal spray for the treatment of spasticity due to multiple sclerosis (MS). Sativex is the world’s first prescription cannabis medicine and the UK is the first country in the world to grant a full regulatory authorization for the product.

Sativex contains two cannabinoids or active ingredients – THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol). It is the first cannabinoid medicine derived from whole plant extracts from the cannabis sativa plant.

Sativex, available as a prescription only medicine, was developed by GW in specific response to calls from people with MS for a prescription cannabis-based medicine. Today’s launch means that MS patients suffering the spasms and cramping associated with spasticity have access to a new treatment option which has been shown to improve their symptoms where current treatments have failed.

Sativex is manufactured by GW under Home Office licence at an undisclosed location in the UK. The medicine is being marketed in the UK by GW’s UK licensee, Bayer Schering Pharma.

Dr Geoffrey Guy, GW’s chairman, said: “The approval and launch of Sativex in the UK is the world’s first full approval of a cannabis-derived prescription medicine and the product of eleven year’s research by GW into the cannabinoid system. GW was founded with the primary goal of developing a medicine to address the unmet needs of people with MS and today’s launch of Sativex represents a welcome advance in MS symptom treatment. This is also an historic moment for GW and marks the beginning of the company’s transition from late stage development company to a commercial pharmaceutical business. Today’s news validates our cannabinoid technology platform and enables us to progress the development of our pipeline across a range of therapeutic areas with increased confidence.”

Under the terms of the agreement with Bayer, GW will receive a £10m milestone payment in respect of the UK approval of Sativex.

Outside the UK, Sativex is expected to be approved in Spain shortly. Further submissions will be made in additional European countries during the second half of 2010 under the mutual recognition procedure. Almirall S.A. will market Sativex in Europe (ex-UK).

Click here for source.

Advertisements

One thought on “♣ GW Pharma launches world’s first prescription cannabis medicine Sativex in UK

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s